Back to search results

VTX2735 for Recurrent Pericarditis

This study is looking into VTX2735 to see if it is safe and works well for people who have recurrent pericarditis (inflammation of the sac around the heart that keeps coming back). We want to understand how different doses of VTX2735 affect the condition. You might be able to join if you are between 18 and 75 years old, have had pericarditis before, and are currently experiencing symptoms or are likely to have another episode soon. The main goal is to check the safety of VTX2735 over a period of up to 26 weeks. This study plans to enroll about 50 participants, but its current status is unclear.

Study design
This is an open-label study, meaning you and the study team will know which dose of VTX2735 you are receiving. It plans to enroll about 50 participants.
What's involved
You would go through a screening period of up to 30 days, followed by different treatment periods with VTX2735 that could last several weeks, and a follow-up period.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 26 weeks after starting treatment, including a 14-day follow-up period after the treatment phases.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06836232

An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis

Recruiting
PHASE2Ages 18–75InterventionalTreatment
Zomagen Biosciences Ltd.
~50 participants
Updated 2026-05-22 on ClinicalTrials.gov
What's tested:VTX2735

At a glance

Recruiting sites
15 of 18 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and tolerability of VTX2735
Measured over Day 1 of treatment period through study completion, up to 26 weeks

Conditions

Recurrent Pericarditis

Explore related trials

Pericarditis

Where it's being run

18 sites across 15 states
Illinois2
Texas2
Virginia2
Arizona1
California1
Florida1
Kentucky1
Massachusetts1

Who to contact

Ventyx Clinical Trial Contact
[email protected]
888-411-5176 · ext. ext 108
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants are male or female ≥ 18 years up to ≤ 75 years of age.
Capable of giving signed informed consent and able to comply with the protocol
Previously had an index (first) episode of pericarditis which met the criteria for an acute pericarditis event
Ongoing symptomatic episode of pericarditis, or may have an episode of recurrent pericarditis in the next 4 weeks.
CRP by local laboratory assessment prior to first dose of study treatment (participants with CRP ≤ 10 mg/L must be receiving corticosteroid treatment for RP and have evidence of pericardial inflammation)
Pericarditis pain score ≥ 4 based on the 11-point NRS.
Stable doses of NSAIDs, colchicine, and/or oral corticosteroids (if receiving these treatments)

Exclusion

Current or prior diagnosis of pericarditis that is secondary to specific prohibited causes, including but not limited to tuberculosis, blunt trauma, tumor, myocarditis, or systemic autoimmune diseases.
History of clinically significant immunosuppressive disorder, autoimmune/autoinflammatory disorder, or primary or secondary immunodeficiency.
Clinically important history of a medical disorder that would compromise safety or data quality, per the Investigator's judgment.

What this trial measures

  • Safety and tolerability of VTX2735Day 1 of treatment period through study completion, up to 26 weeks

    Incidence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to study treatment discontinuation